NASDAQ:NDRA

ENDRA Life Sciences - NDRA Stock Forecast, Price & News

$3.55

-0.04 (-1.06%)

(As of 12/9/2022 12:27 PM ET)

Add

Compare

Today's Range: $3.28
▼
$3.82
50-Day Range: $0.16
▼
$0.34
52-Week Range: $0.16
▼
$0.91

Volume: 3,476 shs
Average Volume: 272,803 shs
Market Capitalization: $224.25 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.63

ENDRA Life Sciences MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 30.3% Upside
$4.63 Price Target
Short Interest: Healthy
0.95% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.45
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$1,700 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.21) to ($0.12) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

353rd out of 1,022 stocks

Electromedical Equipment Industry

8th out of 23 stocks

3.5

Analyst's Opinion

Consensus Rating
ENDRA Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.63, ENDRA Life Sciences has a forecasted upside of 30.3% from its current price of $3.55.
Amount of Analyst Coverage
ENDRA Life Sciences has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.95% of the outstanding shares of ENDRA Life Sciences have been sold short.
Short Interest Ratio / Days to Cover
ENDRA Life Sciences has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in ENDRA Life Sciences has recently increased by 8.77%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
ENDRA Life Sciences does not currently pay a dividend.
Dividend Growth
ENDRA Life Sciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NDRA.

3.0

News and Social Media Coverage

News Sentiment
ENDRA Life Sciences has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for ENDRA Life Sciences this week, compared to 1 article on an average week.
MarketBeat Follows
Only 2 people have added ENDRA Life Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ENDRA Life Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,700.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 5.40% of the stock of ENDRA Life Sciences is held by insiders.
Percentage Held by Institutions
Only 9.88% of the stock of ENDRA Life Sciences is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for ENDRA Life Sciences are expected to grow in the coming year, from ($0.21) to ($0.12) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ENDRA Life Sciences is -14.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ENDRA Life Sciences is -14.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ENDRA Life Sciences has a P/B Ratio of 14.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About ENDRA Life Sciences (NASDAQ:NDRA) Stock

ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

Receive NDRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ENDRA Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

NDRA Stock News Headlines

December 8, 2022 | finance.yahoo.com

Here's Why ENDRA Life Sciences Inc. (NDRA) Could be Great Choice for a Bottom Fisher

December 5, 2022 | finance.yahoo.com

ENDRA Life Sciences Announces 1-for-20 Reverse Stock Split

November 15, 2022 | seekingalpha.com

ENDRA Life Sciences Inc. (NDRA) Q3 2022 Earnings Call Transcript

November 15, 2022 | finance.yahoo.com

ENDRA Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update

November 14, 2022 | marketwatch.com

Electriq Power, EnOcean and TriSalus Life Sciences Sign SPAC Deals to Go Public

November 12, 2022 | msn.com

ENDRA Life Sciences Earnings Preview

November 11, 2022 | bizjournals.com

Chapel Hill transformation rolls on with new Franklin St. development

November 9, 2022 | finance.yahoo.com

ENDRA Life Sciences to Report Third Quarter 2022 Financial Results on November 14, 2022

October 25, 2022 | finance.yahoo.com

ENDRA Life Sciences Enhances TAEUS® System Intellectual Property Portfolio with Issuance of Two U.S. Patents

October 21, 2022 | bizjournals.com

Report: Washington life sciences companies landed over $5B last year

October 15, 2022 | bizjournals.com

‘Smells like science and progress’: Construction begins on Hatch Life Sciences in Long Island City

October 15, 2022 | bizjournals.com

New York’s life-sciences development is too often overlooked, says local developer

October 4, 2022 | finance.yahoo.com

ENDRA Life Sciences to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference

September 29, 2022 | finance.yahoo.com

ENDRA Life Sciences Plans to Submit De Novo Request to U.S. FDA for its TAEUS® System in Coming Weeks

September 29, 2022 | markets.businessinsider.com

Xlife Sciences with pleasing progress in the first half of 2022

September 27, 2022 | finance.yahoo.com

ENDRA Life Sciences Inc. (NDRA)

September 6, 2022 | finance.yahoo.com

ENDRA Life Sciences to Participate in Upcoming Investor and Industry Conferences

August 25, 2022 | seekingalpha.com

ENDRA Life Sciences receives European patent for TAEUS system

August 24, 2022 | finance.yahoo.com

ENDRA Life Sciences Announces Issuance of 8th European Patent for its TAEUS® System

August 17, 2022 | uk.investing.com

ENDRA Life Sciences Reports In-Line Q2 EPS

August 16, 2022 | seekingalpha.com

ENDRA Life Sciences Inc. (NDRA) CEO Francois Michelon on Q2 2022 Results - Earnings Call Transcript

August 16, 2022 | finance.yahoo.com

ENDRA Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update

August 14, 2022 | seekingalpha.com

Endra Life Sciences Q2 2022 Earnings Preview

August 12, 2022 | msn.com

Preview: ENDRA Life Sciences Earnings

August 8, 2022 | finance.yahoo.com

Here's Why ENDRA Life Sciences (NASDAQ:NDRA) Must Use Its Cash Wisely

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive NDRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ENDRA Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

NDRA Company Calendar

Last Earnings: 11/14/2022
Today: 12/09/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/29/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Electromedical equipment
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NDRA
CUSIP: N/A
CIK: 1681682
Web: www.endrainc.com
Phone: (734) 335-0468
Fax: N/A
Employees: 18
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $4.63
High Stock Price Forecast: $5.00
Low Stock Price Forecast: $4.25
Forecasted Upside/Downside: +30.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.25)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-11,230,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -119.79%
Return on Assets: -101.00%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.78
Quick Ratio: 5.24

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.25 per share
Price / Book: 14.20

Miscellaneous

Outstanding Shares: 63,170,000
Free Float: 59,763,000
Market Cap: $224.25 million
Optionable: Not Optionable
Beta: 0.93

Key Executives

Mr. Francois Michelon (Age 56)
Chairman, Pres & CEO
Comp: $511.64k

Mr. Michael Thornton (Age 54)
Chief Technology Officer
Comp: $358.75k

Mr. Renaud Bertrand Maloberti (Age 53)
Chief Commercial Officer
Comp: $321.53k

Dr. Jonathan Behr Ph.D.
Co-Founder

Ms. Irina Pestrikova (Age 35)
Sr. Director of Fin. & Sec.

Mr. Steve Freeman
HR Leader

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NDRA Stock - Frequently Asked Questions

Should I buy or sell ENDRA Life Sciences stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ENDRA Life Sciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" NDRA shares.
View NDRA analyst ratings or view top-rated stocks.
What is ENDRA Life Sciences' stock price forecast for 2023?: 1 analysts have issued 12 month target prices for ENDRA Life Sciences' stock. Their NDRA share price forecasts range from $4.25 to $5.00. On average, they anticipate the company's stock price to reach $4.63 in the next twelve months. This suggests a possible upside of 30.3% from the stock's current price.
View analysts price targets for NDRA or view top-rated stocks among Wall Street analysts.
How have NDRA shares performed in 2022?: ENDRA Life Sciences' stock was trading at $0.6918 at the beginning of the year. Since then, NDRA shares have increased by 413.2% and is now trading at $3.55.
View the best growth stocks for 2022 here.
When is ENDRA Life Sciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our NDRA earnings forecast.
How were ENDRA Life Sciences' earnings last quarter?: ENDRA Life Sciences Inc. (NASDAQ:NDRA) announced its quarterly earnings results on Monday, November, 14th. The company reported ($0.05) earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.01.
What other stocks do shareholders of ENDRA Life Sciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ENDRA Life Sciences investors own include Advanced Micro Devices (AMD), Trevena (TRVN), VBI Vaccines (VBIV), Ampio Pharmaceuticals (AMPE), Bionano Genomics (BNGO), OPKO Health (OPK), TherapeuticsMD (TXMD), Vista Gold (VGZ), electroCore (ECOR) and Genocea Biosciences (GNCA).

When did ENDRA Life Sciences IPO?: (NDRA) raised $10 million in an initial public offering (IPO) on Friday, February 3rd 2017. The company issued 2,000,000 shares at a price of $5.00-$5.50 per share. Dougherty & Company and Dawson James Securities served as the underwriters for the IPO.
What is ENDRA Life Sciences' stock symbol?: ENDRA Life Sciences trades on the NASDAQ under the ticker symbol "NDRA."
Who are ENDRA Life Sciences' major shareholders?: ENDRA Life Sciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (1.58%) and Renaissance Technologies LLC (0.45%). Insiders that own company stock include Alexander Y Tokman, Anthony Digiandomenico, David R Wells, Francois Roger Michelon, Lou Basenese, Michael Milos Thornton and Renaud Bertrand Maloberti.
View institutional ownership trends.
How do I buy shares of ENDRA Life Sciences?: Shares of NDRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is ENDRA Life Sciences' stock price today?: One share of NDRA stock can currently be purchased for approximately $3.55.
How much money does ENDRA Life Sciences make?: ENDRA Life Sciences (NASDAQ:NDRA) has a market capitalization of $224.25 million. The company earns $-11,230,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis.
How can I contact ENDRA Life Sciences?: ENDRA Life Sciences' mailing address is 3600 GREEN COURT SUITE 350, ANN ARBOR MI, 48105. The official website for the company is www.endrainc.com. The company can be reached via phone at (734) 335-0468 or via email at ndra@mzgroup.us.

This page (NASDAQ:NDRA) was last updated on 12/9/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial